论文部分内容阅读
目的 :探讨严重急性呼吸综合征 (SARS)治疗过程中抗病毒药物的应用。方法 :对收治的 2 4例 SARS患者均应用抗病毒药物利巴韦林 ,其中 10例患者合并使用抗菌药物 ,7例合并使用糖皮质激素。利巴韦林静脉滴注 5 0 0 m g,1次 / d,合并应用激素者剂量适当加大 ,出现消化道症状者 2周后停药或减量 ;平均剂量为 (4 5 0± 70 .8) mg/ d。结果 :经上述药物治疗后所有患者临床症状均明显改善 ,无 1例患者发生呼吸衰竭 ,仅有 2例患者出现食欲下降。用药后 PL T由 (2 2 2 .79± 5 6 .36 )× 10 9/ L升至 (2 5 4 .13± 5 0 .0 4 )× 10 9/ L,HCT由 (0 .39± 0 .0 4 )升至 (0 .4 0± 0 .0 4 ) ,均无统计学差异。 结论 :以利巴韦林为主的抗病毒疗法 ,合并应用抗菌药物、糖皮质激素等 ,可有效治疗 SARS患者 ,无明显不良作用
Objective: To investigate the application of antiviral drugs in the treatment of severe acute respiratory syndrome (SARS). Methods: Antiviral drug ribavirin was administered to 24 infants with SARS. Ten patients combined with antimicrobial agents and seven received glucocorticoid. Ribavirin intravenous infusion of 500 mg, 1 / d, combined with hormone appropriate dose increase, the occurrence of gastrointestinal symptoms were discontinued or reduced after 2 weeks; the average dose was (450 ± 70. 8) mg / d. Results: The clinical symptoms of all patients were significantly improved after treatment with the above drugs. No patient developed respiratory failure and only 2 patients experienced loss of appetite. PLT increased from (2 2 2 .79 ± 5 6 .36) × 10 9 / L to (2 5 4 .13 ± 5 0 .0 4) × 10 9 / L after treatment, and HCT decreased from (0 .39 ± 0. 0 4) to (0. 0 ± 0. 0 4), no statistical difference. Conclusion: Ribavirin-based antiviral therapy combined with antimicrobial agents and glucocorticoids can effectively treat SARS patients without obvious adverse effects